Researchers launch 1 million-record dog and cat tumor registry

March 29, 2026 · Updated March 30, 2026 · 11 sources

clinical-researchoncologycanine-medicinefeline-medicinedata-science

CURRENT FULL VERSION: A new open-source tumor registry from the University of Liverpool and the University of Las Palmas de Gran Canaria aims to give veterinary oncology something it has long lacked: scale. The collaborators say the database now contains more than 1 million canine and feline tumor records, making it the largest open-source resource of its kind and a major expansion from an earlier SAVSNET pathology-based registry that described 100,000 UK dog and cat tumors in 2021. (phys.org)

That growth matters because veterinary cancer surveillance has historically been patchy. Reviews published in 2025 note that animal cancer registries remain fragmented globally, with inconsistent diagnostic criteria, uneven coding standards, and limited centralized data-sharing, even as dogs and cats are increasingly recognized as important comparative oncology models. In practical terms, that has made it harder to compare findings across institutions, study rare tumors, or generate robust risk estimates for specific breeds and subpopulations. (sciencedirect.com)

According to the University of Liverpool’s announcement, the new registry was built by working with veterinary diagnostic laboratories and applying methods to extract and standardize pathology data into a unified dataset. The team says the resource includes more than 150 tumor types across more than 200 breeds, and that researchers worldwide will be able to use it to investigate patterns that were previously obscured by fragmented reporting. The announcement also says early analyses have already raised questions about breed-linked tumor risk and the possible influence of neutering practices on certain cancers. (phys.org)

One early output tied to the registry is a 2026 paper in Veterinary and Comparative Oncology, “Epidemiology of Four Major Canine Tumours in the UK: Insights From a National Pathology Registry With Comparative Oncology Perspectives.” Repository metadata for that paper lists keywords including mast cell tumour, osteosarcoma, haemangiosarcoma, melanoma, breed risk, and comparative oncology, suggesting the database is already being used to move beyond simple case counts toward more clinically relevant epidemiologic analysis. (livrepository.liverpool.ac.uk)

The broader field has been moving in this direction for some time. The earlier 2021 SAVSNET tumor-registry paper described a text-mining approach that pulled data from diagnostic pathology records across the UK, but it also acknowledged a core limitation shared by many veterinary registries: lack of a clearly defined population at risk. More recent literature continues to stress that standardization, interoperability, and privacy frameworks are still immature in veterinary medicine, especially when data are being pooled across labs and institutions for oncology and AI-enabled research. That means the new 1 million-record registry is a meaningful infrastructure advance, but not the end of the methodological work. (nature.com)

That infrastructure story is arriving alongside a separate wave of molecular oncology work, especially in cats. A large international study published in Science performed targeted sequencing on 493 feline tumor-normal pairs across 13 cancer types from five countries, creating what researchers described as the first large-scale genetic map of feline cancer. Across the cohort, TP53 was the most frequently mutated gene, appearing in roughly a third of tumors, and recurrent alterations were also identified in genes including FBXW7, CTNNB1, PTEN, and TRAF3. The study strengthens the case that naturally occurring feline cancers are not just clinically important in their own right, but also useful comparative models because cats share many environmental exposures with humans and develop cancers with overlapping genetic drivers. (Vet Candy Radio, Veterinary medicine news)

Some of the most clinically interesting signals came from feline mammary carcinoma, one of the most common and aggressive feline cancers. Reporting on the Science study highlighted FBXW7 mutations in more than half of feline mammary tumors and PIK3CA alterations in a substantial share as well, with parallels to human breast cancer biology. Investigators also reported preliminary laboratory evidence that tumors carrying FBXW7 mutations showed greater sensitivity to certain chemotherapy drugs, while PIK3CA is already a targetable pathway in human oncology. Those findings do not yet translate into standard-of-care treatment changes for cats, but they illustrate the kind of precision-oncology questions that become more realistic when large pathology registries and large genomic datasets start to complement each other. (Vet Candy Radio, Animal Health News and Views)

The feline work also helps explain why better-scale veterinary datasets matter beyond dogs. The 13 tumor types studied included common feline presentations such as cutaneous squamous cell carcinoma, lung adenocarcinoma, lymphoma, and mammary carcinoma. Researchers reported potentially actionable alterations in a subset of tumors and described tumor-specific patterns such as frequent MYC copy-number gain in T-cell lymphoma. At the same time, more conventional pathology studies continue to show where the clinical burden sits: a long-term institutional cohort of male dogs and cats with mammary tumors found these tumors were predominantly malignant in both species, with a particularly aggressive profile in male cats, where intermediate- and high-grade tumors were more common. (Vet Candy Radio, Wiley)

Another strand of comparative work is pushing toward treatment prediction, not just tumor cataloging. In pet dogs with diffuse large B-cell lymphoma, researchers from Tufts and UMass Chan analyzed serial blood samples from a prior clinical trial testing lower-intensity chemo-immunotherapy regimens plus experimental immune-boosting therapies. They found that expression of immune-related genes in circulating blood cells, including CD1E and CCL14, was associated with longer survival, suggesting that blood-based immune signatures could eventually help identify poor responders earlier and support more personalized treatment choices in both veterinary and human oncology. It is a different kind of dataset than a pathology registry, but it points in the same direction: veterinary cancer care is becoming more data-rich, more longitudinal, and potentially more precise. (Newswise)

Why it matters: For practicing veterinarians, large registries can eventually sharpen conversations that happen every day in exam rooms and referral settings: whether a lesion pattern is typical for a breed, how age and reproductive status may shape risk, and when a case fits a common presentation versus an outlier that deserves a different diagnostic workup. For oncologists and pathologists, the value is even more immediate. Bigger registries make it easier to study uncommon tumors, improve case classification, and generate hypotheses for comparative oncology, where naturally occurring cancers in dogs and cats may inform human cancer biology and vice versa. That’s especially relevant in cats, which remain comparatively under-studied despite often having a higher proportion of malignant tumors than dogs. Recent feline genomics work now gives that point more substance: it suggests cats share meaningful cancer-driver mutations with humans, particularly in aggressive mammary tumors, and may eventually help bridge pathology, genomics, and treatment-response research in a way the field has not previously been able to do at scale. (sciencedirect.com, Vet Candy Radio)

There’s also a business and systems angle. As veterinary oncology becomes more data-driven, registries like this could influence diagnostic-lab partnerships, clinical research recruitment, and eventually decision-support tools built on real-world pathology data. But the utility of those tools will depend on how well the underlying data are harmonized, how representative they are of the wider pet population, and whether privacy and governance standards keep pace. Recent commentary in Veterinary Oncology argues those issues are becoming increasingly important as AI and multi-institutional oncology datasets expand. The same is true if the field hopes to connect registry-scale pathology data with genomic resources, liquid-biopsy style monitoring, or future precision-medicine trials in dogs and cats. (veterinaryoncology.biomedcentral.com, Newswise)

What to watch: Expect follow-on studies from this registry, especially around breed-associated risk, rare tumors, and comparative oncology questions, plus possible expansion to more laboratories and real-time surveillance. The key milestone to watch is whether researchers can pair this pathology database with stronger denominator data from the broader dog and cat population, which would make risk estimates more actionable for frontline veterinary care. A second milestone is whether registry-scale surveillance starts linking more directly with molecular profiling and treatment-response work, particularly in under-studied feline cancers where recent genomic studies have already identified plausible therapeutic targets and human-relevant biology. (phys.org, Vet Candy Radio, Newswise)

← Brief version

Like what you're reading?